| |
| |
|
| Insider
Information: |
Friedman Paul A |
| Relationship: |
Director |
| City: |
Palo Lato |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
964,465 |
|
|
Indirect Shares
|
670,540 |
|
|
| Direct
Value |
$60,716,225 |
|
|
|
Indirect Value
|
$161,810,515 |
|
|
| Total
Shares |
1,635,005 |
|
|
| Total
Value |
$222,526,740 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 14.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Incyte Corp |
INCY |
Director |
2020-05-26 |
256,813 |
2020-05-26 |
15,000 |
Premium* |
|
|
Bausch & Lomb, Inc. |
BOL.04 |
Director |
2007-10-26 |
0 |
2004-06-01 |
0 |
Premium* |
|
|
Verastem, Inc. |
VSTM |
Director |
2014-12-24 |
3,000 |
2014-12-24 |
0 |
Premium* |
|
|
Madrigal Pharmaceuticals Inc |
MDGL |
|
2024-04-08 |
185,735 |
2024-04-08 |
655,540 |
Premium* |
|
|
Dare Bioscience Inc |
DARE |
Director |
2017-04-03 |
18,819 |
2016-10-03 |
0 |
Premium* |
|
|
Alexion Pharmaceuticals Inc |
ALXN |
Director |
2021-07-21 |
0 |
2017-11-29 |
0 |
Premium* |
|
|
Prelude Therapeutics Inc |
PRLD |
Director |
2020-09-29 |
500,098 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| INCY |
Incyte Corp |
Chief Executive Officer |
• – – |
2013-09-10 |
4 |
S |
$37.32 |
$14,061,765 |
D/D |
(376,789) |
391,868 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2014-02-14 |
4 |
S |
$65.52 |
$670,073 |
D/D |
(10,227) |
417,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2014-02-18 |
4 |
S |
$65.82 |
$47,392,770 |
D/D |
(720,036) |
417,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2014-02-19 |
4 |
S |
$62.66 |
$2,563,985 |
D/D |
(40,919) |
417,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2014-02-20 |
4 |
S |
$63.51 |
$2,118,313 |
D/D |
(33,354) |
417,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2014-11-06 |
4 |
S |
$67.87 |
$12,600,269 |
D/D |
(185,653) |
417,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2015-02-13 |
4 |
S |
$74.25 |
$8,918,400 |
D/D |
(120,000) |
297,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2015-05-21 |
4 |
S |
$108.75 |
$2,465,742 |
D/D |
(22,651) |
297,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2015-05-22 |
4 |
S |
$107.75 |
$8,599,179 |
D/D |
(79,592) |
297,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2015-05-26 |
4 |
S |
$107.00 |
$13,661,652 |
D/D |
(127,619) |
297,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2015-05-27 |
4 |
S |
$107.19 |
$7,435,026 |
D/D |
(69,132) |
297,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2015-11-17 |
4 |
S |
$111.37 |
$11,196,269 |
D/D |
(100,000) |
297,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2015-11-18 |
4 |
S |
$115.12 |
$14,415,840 |
D/D |
(125,000) |
297,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2017-02-23 |
4 |
S |
$120.32 |
$6,016,000 |
D/D |
(50,000) |
297,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2017-03-16 |
4 |
S |
$151.45 |
$1,258,095 |
D/D |
(8,307) |
297,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2017-03-17 |
4 |
S |
$148.18 |
$6,178,069 |
D/D |
(41,693) |
297,518 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2017-11-16 |
4 |
S |
$105.24 |
$3,000,077 |
D/D |
(28,507) |
269,011 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Chief Executive Officer |
• • – |
2018-06-11 |
4 |
S |
$287.46 |
$21,135,784 |
I/I |
(73,526) |
655,540 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2019-08-02 |
4 |
S |
$84.41 |
$1,862,591 |
D/D |
(22,066) |
255,531 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2019-08-06 |
4 |
S |
$82.20 |
$6,406,175 |
D/D |
(77,934) |
255,531 |
0 |
- |
|
| INCY |
Incyte Corp |
Chief Executive Officer |
• • – |
2005-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
116,700 |
|
- |
|
| INCY |
Incyte Corp |
officerTitle |
• • – |
2005-11-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
169,400 |
|
- |
|
| BOL.04 |
Bausch & Lomb, Inc. |
Director |
– • – |
2007-09-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
776 |
2,286 |
0 |
- |
|
| BOL.04 |
Bausch & Lomb, Inc. |
Director |
– • – |
2007-10-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
865 |
0 |
0 |
- |
|
| INCY |
Incyte Corp |
Chief Executive Officer |
• • – |
2010-07-07 |
4 |
OE |
$5.46 |
$155,034 |
D/D |
25,142 |
289,707 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
